The recent development of immune checkpoint inhibitors (ICIs) targeting PD‐1 and programmed cell death‐ligand 1 (PD‐L1) have contributed to improvements in the prognosis of many cancer patients [27, 28, 29]. This evidence concerns the gene CD274 and cancer.